LOWERING THE COST OF PRESCRIPTION DRUGS - REPLY

被引：0
|
作者：
FRAZIER, LM
BROWN, JT
DIVINE, GW
机构：
来源：
ANNALS OF INTERNAL MEDICINE | 1991年 / 115卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：749 / 749
页数：1
相关论文
共 50 条
  • [31] Comment: Regulations for pediatric labeling of prescription drugs - Reply
    Nahata, MC
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (09) : 1093 - 1093
  • [32] ALLEGED DIRECT PROMOTION OF PRESCRIPTION DRUGS TO CONSUMERS - REPLY
    DEFESCHE, CL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (03): : 182 - 182
  • [33] Managed care cost containment involving prescription drugs
    Latham, S
    [J]. FOOD AND DRUG LAW JOURNAL, 1998, 53 (01): : 25 - 34
  • [34] THE DEMAND FOR PRESCRIPTION DRUGS AS A FUNCTION OF COST-SHARING
    LEIBOWITZ, A
    MANNING, WG
    NEWHOUSE, JP
    [J]. SOCIAL SCIENCE & MEDICINE, 1985, 21 (10) : 1063 - 1069
  • [35] Industry-to-physician marketing and the cost of prescription drugs
    Chiong, W
    [J]. AMERICAN JOURNAL OF BIOETHICS, 2003, 3 (03): : W28 - W29
  • [36] Cost Effectiveness and Cancer Drugs Reply
    Pfister, David G.
    Baxi, Shrujal S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1092 - 1093
  • [37] Increasing prescription of drugs for secondary prevention of myocardial infarction - Lipid lowering drugs should be considered too
    Taylor, A
    Reckless, JP
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1996, 312 (7025): : 252 - 252
  • [38] Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation
    Califf, Robert M.
    Slavitt, Andrew
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (16): : 1571 - 1573
  • [39] Cost of care for patients treated with lipid-lowering drugs
    Åsa Carlsson
    Fredrik Borgström
    Jan Stålhammar
    Evo Alemao
    Don Yin
    Linus Jönsson
    [J]. PharmacoEconomics, 2004, 22 : 25 - 35
  • [40] Cost of care for patients treated with lipid-lowering drugs
    Carlsson, Å
    Borgström, F
    Stålhammar, J
    Alemao, E
    Yin, D
    Jönsson, L
    [J]. PHARMACOECONOMICS, 2004, 22 (Suppl 3) : 25 - 35
12345